HUMACYTE ($HUMA) posted quarterly earnings results on Wednesday, November 12th. The company reported earnings of -$0.14 per share, beating estimates of -$0.16 by $0.02. The company also reported revenue of $750,000, missing estimates of $940,776 by $-190,776.
You can see Quiver Quantitative's $HUMA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HUMACYTE Insider Trading Activity
HUMACYTE insiders have traded $HUMA stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- BRADY W DOUGAN has made 0 purchases and 3 sales selling 2,241,045 shares for an estimated $3,733,191.
- LAURA E NIKLASON (President, CEO and Director) has made 0 purchases and 3 sales selling 2,241,045 shares for an estimated $3,733,191.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
HUMACYTE Hedge Fund Activity
We have seen 77 institutional investors add shares of HUMACYTE stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HEIGHTS CAPITAL MANAGEMENT, INC removed 4,025,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $8,412,250
- RA CAPITAL MANAGEMENT, L.P. removed 3,312,356 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,922,824
- CENTERBOOK PARTNERS LP removed 3,146,628 shares (-91.7%) from their portfolio in Q3 2025, for an estimated $5,475,132
- MARSHALL WACE, LLP added 2,590,394 shares (+5308.2%) to their portfolio in Q2 2025, for an estimated $5,413,923
- CITADEL ADVISORS LLC removed 2,287,143 shares (-78.5%) from their portfolio in Q2 2025, for an estimated $4,780,128
- TORONTO DOMINION BANK removed 2,131,390 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,454,605
- MONASHEE INVESTMENT MANAGEMENT LLC removed 2,000,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,179,999
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
HUMACYTE Analyst Ratings
Wall Street analysts have issued reports on $HUMA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 11/10/2025
- BTIG issued a "Buy" rating on 10/13/2025
- Barclays issued a "Overweight" rating on 08/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/12/2025
To track analyst ratings and price targets for HUMACYTE, check out Quiver Quantitative's $HUMA forecast page.
HUMACYTE Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 5 analysts offer price targets for $HUMA in the last 6 months, with a median target of $3.5.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 11/10/2025
- Ryan Zimmerman from BTIG set a target price of $6.0 on 10/13/2025
- Matt Miksic from Barclays set a target price of $3.5 on 08/27/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $3.0 on 08/12/2025
- Joshua Jennings from TD Cowen set a target price of $3.5 on 08/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
